Erectile dysfunction affects 50% of men between 40 and 70 to some degree. The majority have a vascular cause. Pills work around that cause. Shockwave therapy and PRP address it directly. The difference is significant.
The vascular mechanism of ED
An erection depends on adequate blood flow into the cavernous tissue of the penis, mediated by nitric oxide-driven smooth muscle relaxation in the cavernous arteries. When the arterial response is impaired, due to atherosclerosis, endothelial dysfunction, or the chronic micro-vascular disease that accompanies metabolic syndrome, hypertension and diabetes, the blood flow achieved is insufficient for reliable erection.
This vasculogenic mechanism accounts for the majority of ED presentations in men over 40. The proportion rises with age and the accumulation of cardiovascular risk factors: by 70, the majority of ED is significantly or predominantly vascular. ED is, in fact, now recognised as an early indicator of systemic cardiovascular disease, the penile vasculature is smaller and more sensitive to endothelial dysfunction than the coronary vasculature, and ED frequently precedes coronary events by 5–10 years.
PDE5 inhibitors: the pharmacological workaround
Sildenafil (Viagra), tadalafil (Cialis) and vardenafil inhibit the enzyme phosphodiesterase type 5 (PDE5), which normally degrades cyclic GMP, the second messenger in the nitric oxide signalling pathway. By inhibiting PDE5, these medications allow the residual nitric oxide response to produce more prolonged smooth muscle relaxation and improved blood flow. They amplify a response that already exists.
This is effective when there is sufficient vascular function remaining to amplify. As the underlying vascular disease progresses, as endothelial function declines further and cavernous arterial compliance reduces, PDE5 inhibitors become progressively less effective because there is less residual response to amplify. Approximately 30–35% of men with ED do not respond adequately to PDE5 inhibitors. Many who initially respond find efficacy declining over years of use as the vascular disease advances.
Critically, PDE5 inhibitors do not improve the underlying vasculature. They are taken before intercourse, produce a response that lasts hours, and have no lasting impact on the vascular biology driving the ED. When the pill wears off, the ED returns unchanged.
LI-ESWT: addressing the mechanism
Low-Intensity Extracorporeal Shockwave Therapy for ED applies low-energy acoustic waves to the cavernous tissue, stimulating the biological processes that restore the vascular mechanism rather than temporarily bypassing it. The key mechanisms are neovascularisation (the formation of new blood vessels through upregulation of VEGF and other angiogenic factors), endothelial function restoration, and the activation of progenitor cells that contribute to vascular repair.
Multiple RCTs have demonstrated significant improvements in IIEF (International Index of Erectile Function) scores following standard LI-ESWT protocols. The 2019 meta-analysis by Sokolakis and Hatzichristodoulou reviewed seven RCTs involving over 600 patients and found significant IIEF improvement in the LI-ESWT group versus sham at follow-up. Crucially, these improvements persisted at 12 months post-treatment, suggesting that the biological changes were sustained beyond the treatment period.
PRP: the growth factor enhancement
PRP combined with LI-ESWT provides an additional angiogenic stimulus via the growth factors concentrated in the centrifuged plasma, particularly PDGF and VEGF, which directly stimulate new blood vessel formation and endothelial repair. Several studies have found the combination superior to LI-ESWT alone for penile tissue vascular markers, though the evidence base is smaller.
PRP can also be used as a standalone treatment in mild ED or as maintenance following an LI-ESWT course, the growth factor stimulus maintaining the vascular improvements achieved through shockwave.
"ED is a vascular disease. Treating it with a pill that temporarily improves blood flow is treating a symptom. LI-ESWT treats the endothelial dysfunction and micro-vascular disease that caused the problem, and the evidence supporting this is now extensive."
Who responds best
LI-ESWT produces the best results in men with mild to moderate vasculogenic ED, those who have some vascular function remaining for the shockwave to enhance and rebuild. Severe ED with near-complete vascular failure responds less well, as does neurogenic ED (caused by nerve damage from radical prostatectomy, diabetes or neurological disease) where the neural signalling pathway rather than the vascular response is primarily impaired.
A thorough consultation establishes the likely underlying mechanism and sets realistic expectations for the individual client's presentation, not population-level averages.
Treatments that work. Results you can see.
Every treatment at Aesthetics Medispa begins with a consultation.